Senior scientists from Lupin, Mankind Pharma | Bharat Serums and Vaccines, Zydus Lifesciences, Panacea Biotec, Veeda Lifesciences, Shilpa Biologicals, Zumutor Biologics, InoRx and Mumbai Biocluster will discuss India's roadmap to becoming a global biosimilars and biologics hub
Indian Pharma Post will host an exclusive virtual webinar, "Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma," on Friday, July 17, 2026, bringing together leading experts from India's biopharmaceutical industry to discuss the country's next phase of growth in biologics and biosimilars.
Scheduled from 3:00 PM to 4:30 PM IST, the webinar comes at a time when biosimilars and biologics are transforming the pharmaceutical industry from a volume-driven generics model to high-value, innovation-led therapies.
With the global biosimilars market projected to reach $150 billion by 2033, the sector presents a significant opportunity for India to strengthen its position as a global biopharma hub.
India's strong scientific talent pool, cost-efficient manufacturing capabilities and established generics industry provide a solid foundation for growth. However, scaling the biologics ecosystem will require addressing challenges such as high capital requirements, complex manufacturing processes, evolving regulatory frameworks and increasing global competition.
The webinar will explore market opportunities, policy initiatives, regulatory pathways, innovation strategies and investment priorities needed to strengthen India's leadership in the global biosimilars and biologics landscape.
The discussion will cover India's transition from volume-led generics to value-driven biologics, opportunities in monoclonal antibodies, insulin, oncology and autoimmune therapies, the role of government initiatives such as Biopharma SHAKTI and the Production Linked Incentive (PLI) scheme, and navigating regulatory pathways including CDSCO, USFDA, EMA, MHRA and WHO standards.
The panel will also examine strategies for building biologics research, development and manufacturing capabilities, leveraging India's talent pool and cost advantages, addressing funding challenges for biopharma innovation, and creating a roadmap to position India as a leading global destination for biologics and biosimilars.
The distinguished speaker lineup includes Dr. Cyrus Karkaria, President – Biotech Businesses, Lupin Limited; Dr. Anil Koul, Group CSO, Mankind Pharma | Bharat Serums and Vaccines; Dr. Kapil Maithal, President – Vaccines & Diagnostics, Zydus Lifesciences Limited; Dr. Amulya K. Panda, Associate Director, Panacea Biotec Limited; Dr. Sanjib Banerjee, COO (Biopharma), Veeda Lifesciences Limited; Dr. Puspadhwaja Mall, Head, R&D, Operations and Portfolio Management, Shilpa Biologicals; Dr. Ratnesh Jain, Founder and Director, Mumbai Biocluster; Dr. Maloy Ghosh, Chief Scientific Officer, Zumutor Biologics; and Dr. Melvin George, Chief Medical Officer, InoRx.
The session will be moderated by Rahul Koul, Editor, Indian Pharma Post, and will conclude with a live interactive Q&A, providing participants an opportunity to engage directly with industry leaders.
The webinar is designed for CEOs, managing directors, business leaders, R&D professionals, biologics and biosimilars experts, regulatory and quality professionals, manufacturing leaders, investors, consultants, researchers and healthcare innovators.
Participants will gain insights into one of the fastest-growing segments of global healthcare, understand emerging regulatory and market trends, learn strategies to accelerate innovation and global market access, and explore opportunities for collaboration, investment and business growth in India's rapidly evolving biopharmaceutical sector.
Event Details
Subscribe To Our Newsletter & Stay Updated
